Long-term outcome of perianal fistulizing crohn's disease treated with infliximab

Clinical Gastroenterology and Hepatology

Volumn 11, Issue 8, 2013, Pages 975-981.e4

  Bouguen, Guillaume ^a   Siproudhis, Laurent ^a   Gizard, Emmanuel ^b   Wallenhorst, Timothée ^a   Billioud, Vincent ^b   Bretagne, Jean François ^a   Bigard, Marc André ^b   Peyrin Biroulet, Laurent ^b  

^a RENNES UNIVERSITY HOSPITAL   (France)

^b UNIVERSITY HOSPITAL OF NANCY   (France)

Author keywords

IBD therapy; Inflammatory bowel disease; Perianal disease; Tumor necrosis factor antagonist

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CERTOLIZUMAB PEGOL; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; STEROID;

ABDOMINAL DRAINAGE; ABDOMINAL SURGERY; ADULT; ANUS FISTULA; ARTICLE; CLINICAL ASSESSMENT; CROHN DISEASE; DISEASE DURATION; FEMALE; FOLLOW UP; HUMAN; ILEOSTOMY; IMMUNOSUPPRESSIVE TREATMENT; LONG TERM CARE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT REFERRAL; PERIANAL ABSCESS; PERIANAL FISTULIZING CROHN DISEASE; PROCTOCOLECTOMY; RECTUM RESECTION; RECURRENT DISEASE; THERAPY EFFECT;

EID: 84875490499     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2012.12.042     Document Type: Article

References (32)

1. Schwartz D.A. Editorial: imaging and the treatment of Crohn's perianal fistulas-to see is to believe. Am J Gastroenterol 2009, 104:2987-2989.
2. Ingle S.B., Loftus E.V. The natural history of perianal Crohn's disease. Dig Liver Dis 2007, 39:963-969.
3. Schwartz D.A., Loftus E.V., Tremaine W.J., et al. The natural history of fistulizing Crohn's disease in Olmsted County, Minnesota. Gastroenterology 2002, 122:875-880.
4. Mahadev S., Young J.M., Selby W., et al. Quality of life in perianal Crohn's disease: what do patients consider important?. Dis Colon Rectum 2011, 54:579-585.
5. Lapidus A. Crohn's disease in Stockholm County during 19902001: an epidemiological update. World J Gastroenterol 2006, 12:75-81.
6. Lapidus A., Bernell O., Hellers G., et al. Clinical course of colorectal Crohn's disease: a 35-year follow-up study of 507 patients. Gastroenterology 1998, 114:1151-1160.
7. Peyrin-Biroulet L., Loftus E.V., Colombel J.F., et al. The natural history of adult Crohn's disease in population-based cohorts. Am J Gastroenterol 2010, 105:289-297.
8. Tang L.Y., Rawsthorne P., Bernstein C.N. Are perineal and luminal fistulas associated in Crohn's disease? A population-based study. Clin Gastroenterol Hepatol 2006, 4:1130-1134.
9. Hellers G., Bergstrand O., Ewerth S., et al. Occurrence and outcome after primary treatment of anal fistulae in Crohn's disease. Gut 1980, 21:525-527.
10. Peyrin-Biroulet L., Deltenre P., de Suray N., et al. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol 2008, 6:644-653.
11. Present D.H., Rutgeerts P., Targan S., et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999, 340:1398-1405.
12. Sands B.E., Anderson F.H., Bernstein C.N., et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004, 350:876-885.
13. Colombel J.F., Schwartz D.A., Sandborn W.J., et al. Adalimumab for the treatment of fistulas in patients with Crohn's disease. Gut 2009, 58:940-948.
14. Lichtenstein G.R., Hanauer S.B., Sandborn W.J., et al. Management of Crohn's disease in adults. Am J Gastroenterol 2009, 104:465-483. quiz 64, 84.
15. Van Assche G., Dignass A., Reinisch W., et al. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: special situations. J Crohns Colitis 2010, 4:63-101.
16. Antakia R., Shorthouse A.J., Robinson K., et al. Combined modality treatment for complex fistulating perianal Crohn's disease. Colorectal Dis 2013, 15:210-216.
17. Gaertner W.B., Decanini A., Mellgren A., et al. Does infliximab infusion impact results of operative treatment for Crohn's perianal fistulas?. Dis Colon Rectum 2007, 50:1754-1760.
18. Hotokezaka M., Ikeda T., Uchiyama S., et al. Results of seton drainage and infliximab infusion for complex anal Crohn's disease. Hepatogastroenterology 2011, 58:1189-1192.
19. Hyder S.A., Travis S.P., Jewell D.P., et al. Fistulating anal Crohn's disease: results of combined surgical and infliximab treatment. Dis Colon Rectum 2006, 49:1837-1841.
20. Karmiris K., Bielen D., Vanbeckevoort D., et al. Long-term monitoring of infliximab therapy for perianal fistulizing Crohn's disease by using magnetic resonance imaging. Clin Gastroenterol Hepatol 2011, 9:130-136.
21. Roumeguère P., Bouchard D., Pigot F., et al. Combined approach with infliximab, surgery, and methotrexate in severe fistulizing anoperineal Crohn's disease: results from a prospective study. Inflamm Bowel Dis 2011, 17:69-76.
22. Tougeron D., Savoye G., Savoye-Collet C., et al. Predicting factors of fistula healing and clinical remission after infliximab-based combined therapy for perianal fistulizing Crohn's disease. Dig Dis Sci 2009, 54:1746-1752.
23. Uchino M., Ikeuchi H., Bando T., et al. Long-term efficacy of infliximab maintenance therapy for perianal Crohn's disease. World J Gastroenterol 2011, 17:1174-1179.
24. Satsangi J., Silverberg M.S., Vermeire S., et al. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 2006, 55:749-753.
25. Schnitzler F., Fidder H., Ferrante M., et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort. Gut 2009, 58:492-500.
26. Sandborn W.J., Fazio V.W., Feagan B.G., et al. AGA technical review on perianal Crohn's disease. Gastroenterology 2003, 125:1508-1530.
27. Lichtenstein G.R., Diamond R.H., Wagner C.L., et al. Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials. Aliment Pharmacol Ther 2009, 30:210-226.
28. Colombel J.F., Sandborn W.J., Reinisch W., et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010, 362:1383-1395.
29. Ng S.C., Plamondon S., Gupta A., et al. Prospective evaluation of anti-tumor necrosis factor therapy guided by magnetic resonance imaging for Crohn's perineal fistulas. Am J Gastroenterol 2009, 104:2973-2986.
30. Tozer P., Ng S.C., Siddiqui M.R., et al. Long-term MRI-guided combined anti-TNF-alpha and thiopurine therapy for Crohn's perianal fistulas. Inflamm Bowel Dis 2012, 18:1825-1834.
31. Topstad D.R., Panaccione R., Heine J.A., et al. Combined seton placement, infliximab infusion, and maintenance immunosuppressives improve healing rate in fistulizing anorectal Crohn's disease: a single center experience. Dis Colon Rectum 2003, 46:577-583.
32. van der Hagen S.J., Baeten C.G., Soeters P.B., et al. Anti-TNF-alpha (infliximab) used as induction treatment in case of active proctitis in a multistep strategy followed by definitive surgery of complex anal fistulas in Crohn's disease: a preliminary report. Dis Colon Rectum 2005, 48:758-767.